Assessing the Use of Activated Protein C in the Treatment of Severe Sepsis

Publisher Website
Google Scholar
Abstract
In 2001, the Food and Drug Administration (FDA) evaluated an application for the use of drotrecogin alfa (activated), or recombinant human activated protein C (Xigris, Eli Lilly), in patients with severe sepsis. The use of activated protein C, as compared with placebo, was associated with a significant reduction in mortality in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial (24.7 percent vs. 30.8 percent, P=0.005).1 Extensive review by physicians and scientists at the FDA confirmed the principal findings of the PROWESS trial but raised issues regarding the interpretation of data and appropriate use of the . . .

This publication has 5 references indexed in Scilit: